对氧磷酶-1 参与调控非酒精性脂肪肝脂质代谢与胰岛素抵抗作用及机制

肝脏 ›› 2020, Vol. 25 ›› Issue (2): 149-154.

对氧磷酶-1 参与调控非酒精性脂肪肝脂质代谢与胰岛素抵抗作用及机制

张荣, 陈婧, 黄江涛, 吕海龙, 杨一邨, 王浩斌, 张抒

610031 成都市第三人民医院普外科(张荣,黄江涛,吕海龙,杨一邨,王浩斌,张抒);都江堰市人民医院消化内科(陈婧)

收稿日期:2019-06-11 出版日期:2020-02-29 发布日期:2020-03-26
通讯作者: 张抒
基金资助:
国家自然基金(81702963)

The role and mechanism of paraoxonase 1 in the regulation of lipid metabolism and insulin resistance in nonalcoholic fatty liver disease

ZHANG Rong¹, CHEN Jing², HUANG Jiang-tao¹, LU Hai-long¹, YANG Yi-cun¹, WANG Hao-bin¹, ZHANG Shu¹

1. Department of general surgery ,Third People's Hospital of Chengdu, 610031;
2. Department of gastroenterology, Dujiangyan People's Hospital, 611830

Received:2019-06-11 Online:2020-02-29 Published:2020-03-26
Contact: ZHANG Shu

摘要/Abstract

摘要： 目的探究对氧磷酶-1( Paraoxonase 1,PON1)与非酒精性脂肪肝(Nonalcoholic fatty liver disease,NAFLD)脂质代谢与胰岛素抵抗关系及机制。方法选取129例NAFLD患者和130非NAFLD患者为研究对象,收集患者年龄、身高、体重、腰围,血压等信息,检测血脂、空腹血糖(Fast Glucose)、胰高血糖素(Glucagon)、胰岛素(Fast Insulin)、评估胰岛素抵抗的稳态指数(homeostatic index of insulin resistance,HOMA-IR)、肝肾功能、脂肪因子等,LO2细胞接种12孔板培养24 h后分别加入0~1.2 mmol OA溶液处理24 h或10 ng/mL TNF-α处理6 h,以PEI转染空载质粒和PON1质粒 1 μg 24 h。使用尼罗红染料测定细胞内脂质含量。ELISA法检测PON1活性,蛋白质印迹检测PON1、p-IRS1、T-IRS1、p-AKT T-AKT、FAS、HMGCR、SREBP2和SREBP1C蛋白表达。结果 NAFLD患者腰围、BMI、外周血ALT、AST、FFA、TG、TC、LDL-C、VLDL-C、空腹血糖、胰岛素、HOMA-IR、抵抗素、瘦素、IL-6和TNF-α显著高于非NAFLD,PON1活性、含量、HDL-C、胰高血糖素和脂联素显著降低;血PON1活性和含量与FFAs、TG、TC、LDL-C、VLDL-C、空腹血糖、胰岛素、HOMA-IR、抵抗素、瘦素、IL-6和TNF-α显著负相关,与HDL-C、胰高血糖素和脂联素显著正相关;OA组LO2细胞PON1的活性逐渐降低,且0.2~1.2 mM OA组LO2细胞PON1的活性显著低于Control组,过表达PON1不影响PON1活性,0.2~1.2 mM OA组LO2细胞内脂质含量显著高于Control组,显著低于OA组;TNF-α组LO2细胞PON1、p-IRS1、p-AKT、FAS、HMGCR、SREBP2和SREBP1C蛋白表达量相比于Control组显著降低,转染PON1质粒显著增加PON1,同时p-IRS1、p-AKT、FAS、HMGCR、SREBP2和SREBP1C蛋白表达量显著增加。结论 PON1活性与含量和NAFLD血脂代谢及胰岛素抵抗显著相关,且可能通过调控p-IRS1/AKT通路影响胰岛素抵抗,并调控脂质代谢。

关键词: 非酒精性脂肪肝病, 巴拉松酶, 胰岛素抵抗, 脂质代谢, IRS1/AKT通路

Abstract: Objective To investigate the role and mechanism of paraoxonase 1 (PON1) and lipid metabolism,insulin resistance in nonalcoholic fatty liver disease(NAFLD). Methods One hundred and twenty-nine NAFLD patients and 130 non-NAFLD individuals were enrolled in the study. The age, height, weight, waist circumference, blood pressure and other information were collected. Plasma blood lipids, fast glucose, and glucagon were detected by routine blood tests, homeostatic index of insulin resistance (HOMA-IR) was calculated, liver and kidney function were evaluated in biochemical assay, LO2 cells were inoculated in 12-well plates for 24 h and then added 0~ 1.2 mM OA solution was treated for 24 h or 10 ng/mL TNF-α for 6 h, and the 1 μg control and PON1 plasmid were transfected with PEI for 24 h. The intracellular lipid content was determined using a Nile Red dye. PON1 activity was detected by ELISA, and PON1, p-IRS1, T-IRS1, p-AKT T-AKT, FAS, HMGCR, SREBP2 and SREBP1C protein were detected by Western Blot. Results Waist circumference, BMI, peripheral blood ALT, AST, FFAs, TG, TC, LDL-C, VLDL-C, fasting blood glucose, insulin, HOMA-IR, resistin, leptin, IL-6 and TNF-α were significantly higher in patients with NAFLD. In non-NAFLD, PON1 activity, content, HDL-C, glucagon and adiponectin were significantly reduced; PON1 activity and content were significantly negatively correlated with FFAs, TG, TC, LDL-C, VLDL-C, fasting blood glucose, insulin, HOMA -IR, resistin, leptin, IL-6 and TNF-α, and positively correlated with HDL-C, glucagon and adiponectin; PON1 activity in LO2 cells of OA group gradually decreased, and the activity of PON1 in LO2 cells of 0.2~1.2 mM OA group was significantly lower than that of control group. Overexpression of PON1 did not affect PON1 activity, the lipid content of LO2 cells in 0.2~1.2 mM OA group was significantly higher. In the control group, it was significantly lower than the OA group; the expression levels of PON1, p-IRS1, p-AKT, FAS, HMGCR, SREBP2 and SREBP1C in the TNF-α group were significantly lower than those in the control group, and the transfected PON1 plasmid was significantly increased. PON1, while the expression levels of p-IRS1, p-AKT, FAS, HMGCR, SREBP2 and SREBP1C protein were significantly increased. Conclusion PON1 activity and content are significantly correlated with NAFLD lipid metabolism and insulin resistance, and may affect insulin resistance and regulate lipid metabolism by regulating p-IRS1/AKT pathway.

Key words: Nonalcoholic fatty liver disease, Paraoxonase 1, insulin resistance, lipid metabolism, IRS1/AKT pathway

张荣, 陈婧, 黄江涛, 吕海龙, 杨一邨, 王浩斌, 张抒. 对氧磷酶-1 参与调控非酒精性脂肪肝脂质代谢与胰岛素抵抗作用及机制[J]. 肝脏, 2020, 25(2): 149-154.

ZHANG Rong, CHEN Jing, HUANG Jiang-tao, LU Hai-long, YANG Yi-cun, WANG Hao-bin, ZHANG Shu. The role and mechanism of paraoxonase 1 in the regulation of lipid metabolism and insulin resistance in nonalcoholic fatty liver disease[J]. Chinese Hepatolgy, 2020, 25(2): 149-154.

参考文献

[1] Su J, Li J, Yu Q, et al. Association of PON1 gene promoter DNA methylation with the risk of Clopidogrel resistance in patients with coronary artery disease. J Clin Lab Anal, 2019,34: 453-471.
[2] Aluganti N C, Mitra C, Bhardwaj D, et al. Alzheimer's disease markers in aged ApoE-PON1 deficient mice. J Alzheimers Dis, 2019, 67: 1353-1365.
[3] Zhang J, Gao Z, Yin J, et al. S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2. J Biol Chem, 2008, 283: 35375-35382.
[4] Koren-Gluzer M, Aviram M, Hayek T. Paraoxonase1 (PON1) reduces insulin resistance in mice fed a high-fat diet, and promotes GLUT4 overexpression in myocytes, via the IRS-1/Akt pathway. Atherosclerosis, 2013, 229: 71-78.
[5] Samy W, Hassanian M A. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. Arab J Gastroenterol, 2011, 12: 80-85.
[6] van den Berg E H, Gruppen E G, James R W, et al. Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol. J Lipid Res, 2019, 60: 168-175.
[7] Sung K C, Seo D C, Lee S J, et al. Non-alcoholic fatty liver disease and risk of incident diabetes in subjects who are not obese. Nutr Metab Cardiovasc Dis, 2019, 34: 65-78.
[8] 张巍, 邵明亮, 刘素芬等,非酒精性脂肪肝中自噬基因(Beclin-1)与核因子(NF-κBp65)表达研究. 肝脏, 2017, 22: 59-62.
[9] Fedelesova M, Kupcova V, Luha J, et al. Paraoxonase activity in sera of patients with non-alcoholic fatty liver disease. Bratisl Lek Listy, 2017, 118:719-720.
[10] Ben-David M, Soskine M, Dubovetskyi A, et al. Enzyme neo- versus re-functionalization - an epistatic ratchet versus a smooth reversible transition. Mol Biol Evol, 2019, e5686393.
[11] Milaciu MV, Vesa SC, Bocsan IC, et al. Paraoxonase-1 Serum Concentration and PON1 Gene Polymorphisms: Relationship with Non-Alcoholic Fatty Liver Disease. J Clin Med, 2019, 8:e8122200.
[12] Alkhatatbeh M J, Lincz L F, Thorne R F. Low simvastatin concentrations reduce oleic acid-induced steatosis in HepG2 cells: An in vitro model of non-alcoholic fatty liver disease. Exp Ther Med, 2016, 11: 1487-1492.
[13] Morresi C, Cianfruglia L, Sartini D, et al. Effect of high glucose-induced oxidative stress on paraoxonase 2 expression and activity in caco-2 cells.Cells, 2019 8: e8121616.
[14] Ferre N, Marsillach J, Camps J, et al. Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J Hepatol, 2006, 45: 51-59.
[15] Kupczyk D, Bilski R, Sokoowski K, et al. Paraoxonase 1: The Lectin-Like Oxidized LDL Receptor Type I and Oxidative Stress in the Blood of Men with Type II Obesity Dis Markers, 2019,e6178017.